Search

Displaying results 2671 - 2680 of 7540 in total
  1. Drug

    Influenza A Virus A/Sydney/5/2021 SAN-013 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17751
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  2. Drug

    Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17994
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  3. Drug

    Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB17997
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  4. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB19320
    ApprovedWithdrawn

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  5. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB22670
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  6. Drug

    Influenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB22672
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  7. Drug

    Strontium chloride Sr-89

    go.drugbank.com/drugs/DB09498
    Approved

    Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases.

  8. Drug

    Picrotoxin

    go.drugbank.com/drugs/DB00466
    Experimental

    Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem]

  9. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.

  10. Drug

    Zinc chloride

    go.drugbank.com/drugs/DB14533
    Approved

    Zinc chloride is a solution of ions indicated for use in total parenteral nutrition to maintain zinc levels and prevent deficiency syndromes.

    Mixtures: Addamel N, ADDAMEL N